Summary of findings of the Age Related Memory Impairment Trial
(Durham, UK)

Double blind placebo controlled trial assessing the efficacy of the CognitoLite cranial phototherapy device.

The brain requires 20% of the body's basal oxygen to fulfil its function, the mitochondria within the neurons producing the energy for the brain. 

Brain ageing is marked by a range of issues, including decreased antioxidant defences, increased oxidative stress and deficits in mitochondrial oxidative phosphorylation. CognitoLite transcranial PBM-T presents itself as an intervention that could improve neuronal cell function and may well improve cell connectivity and, hence, intellectual function. In this present study, we explored the potential for the beneficial effects’ of 1068 nm PBM-T upon normal healthy middle aged individuals, aged between 45 and 70 years.

The primary outcome measure in the study was the FDA approved computerised psychometric assessment tool, ANAM.
In the active group, six measurements showed significantly improved performance by paired t tests, of which these four were also deemed significant by the sign test:

1. Composite score (measurement of overall performance)
2. Mathematical processing (Working memory)
3. Code substitution delayed (delayed memory)
4. Tapping right hand (motor speed R hand)

In the placebo group, none of the mean changes from baseline were statistically significant, except for processing speed where deterioration in performance was observed.

Twenty percent of the participants of this study who were allocated the active intervention opted to continue treatment for a further 3 months. This cohort was retested monthly using the ANAM assessment tool. All this small cohort continued to make small improvements over the 3 month follow up period suggesting the maximum potential of PBM_T is yet to be fully
evaluated.


Share by: